Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02133183 · ClinicalTrials.gov registry record · Phase 1
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02133183: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02133183 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02133183, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain tumor and how well it works when given before and after surgery in treating patients with glioblastoma that has grown or come back and requires surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Sapanisertib
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-07-02 |
| Est. Completion | 2023-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02133183
The ClinicalTrials.gov registry entry for NCT02133183 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02133183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02133183 about?
NCT02133183 is a clinical study titled "Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma". This partially randomized pilot phase I trial studies how much sapanisertib reaches the brain tumor and how well it works when given before and after surgery in treating patients with glioblastoma that has grown or come back and requires surgery. Sapanisertib may stop the growth of tumor cells by bl...
What is the current status of trial NCT02133183?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-07-02. Estimated completion is 2023-10-31.
What interventions are being tested in trial NCT02133183?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Sapanisertib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02133183?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.